References
- Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392–397.
- Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
- Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807.
- Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–798.
- Tefferi A. How I treat myelofibrosis. Blood 2011;117:3494–3504.
- Green JR, Guenther A. The backbone of progress—preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 2011;77(Suppl. 1):S3–S12.
- Froom P, Elmalah I, Braester A, et al. Clodronate in myelofibrosis: a case report. Am J Med Sci 2002;323:115–116.
- Espanol I, Romagosa V, Berlanga J, et al. Zoledronate-induced remission of acute panmyelosis with myelofibrosis. Eur J Haematol 2004;73:215–218.
- Sivera P, Cesano L, Guerrasio A, et al. Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis. Br J Haematol 1994;86:397–398.
- Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989–1999.
- Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–1491.